Skip to content
Catalyst

knowcompoundsFolic acidfindings

Every finding on folic acid

22 findings, by evidence strength

Direction
Strength, at least

22 shown

  1. Forced expiratory volume in one second (FEV1)Moved: no difference foundEvidence: ModeratePaper: PMID 288846032018
    Who
    Children aged 7 to 10 years at the mid-childhood visit in the Project Viva prospective birth cohort (Massachusetts), by maternal first-trimester folic acid intake from food and supplements (quartiles); whole cohort, not sex-stratified
    Dose studied
    maternal intake from food plus supplements, FFQ, quartiles

    There was no association between maternal folic acid intake and post-FEV1 in the total cohort of children.”

    Quoted verbatim from Folic Acid in Pregnancy and Childhood Asthma: A US Cohort.cohortPermalink
  2. Autism spectrum disorder diagnosis (offspring)Moved: lowersEffect, as reportedOR0.66[0.55 to 0.79]Evidence: ModeratePaper: PMID 412285122025
    Who
    Offspring of mothers who did or did not take folic acid before and/or during pregnancy, pooled from 24 non-randomised studies (case-control, cohort and cross-sectional)
    Dose studied
    not reported

    The MA indicated that maternal folic acid supplementation is associated with a significant reduction in the risk of offspring ASD (pooled OR = 0.66, 95% CI: 0.55–0.79), as shown in the forest plot.”

    Quoted verbatim from The Effect of Maternal Folic Acid Supplementation on Neurodevelopmental Disorders in Offspring: An Umbrella Review of Systematic Reviews and Meta-Analyses.meta-analysisPermalink
  3. Montreal Cognitive Assessment total scoreMoved: raisesEvidence: ModeratePaper: PMID 409459662026
    Who
    Adults aged 40-80 years with cerebral small vessel disease-related cognitive impairment, intention-to-treat analysis at 6 months
    Dose studied
    0.4 mg tablet, two tablets daily, six months

    Specifically, total MoCA score (ITT: β = 1.27; 95 % CI = 0.52, 2.03; PP: β = 1.15; 95 % CI = 0.37, 1.93) and total MMSE score (ITT: β = 0.76; 95 % CI = 0.14, 1.39; PP: β = 0.65; 95 % CI = 0.02, 1.28) were improved among patients with CSVD-CI in the FA intervention group compared with those in the placebo group at follow-ups after adjustment of potential confounders.”

    Quoted verbatim from Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial.RCTPermalink
  4. Mini-Mental State Examination total scoreMoved: raisesEvidence: ModeratePaper: PMID 409459662026
    Who
    Adults aged 40-80 years with cerebral small vessel disease-related cognitive impairment, intention-to-treat analysis at 6 months
    Dose studied
    0.4 mg tablet, two tablets daily, six months

    Specifically, total MoCA score (ITT: β = 1.27; 95 % CI = 0.52, 2.03; PP: β = 1.15; 95 % CI = 0.37, 1.93) and total MMSE score (ITT: β = 0.76; 95 % CI = 0.14, 1.39; PP: β = 0.65; 95 % CI = 0.02, 1.28) were improved among patients with CSVD-CI in the FA intervention group compared with those in the placebo group at follow-ups after adjustment of potential confounders.”

    Quoted verbatim from Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial.RCTPermalink
  5. Colorectal cancer incidenceMoved: no difference foundEffect, as reportedRR1[0.82 to 1.22]Evidence: Moderatereplicated ×1Paper: PMID 261317632015
    Who
    Participants in eight randomized controlled trials of folic acid, total population
    Dose studied
    not reported

    The results suggested that folic acid treatment was not associated with colorectal cancer risk in the total population (relative risk [RR] = 1.00, 95% confidence interval [CI] = 0.82-1.22, P = 0.974).”

    Quoted verbatim from Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials.meta-analysisPermalink
  6. Preterm birth incidenceMoved: no difference foundEvidence: Moderatereplicated ×1Paper: PMID 355775772022An author is affiliated with a producer
    Who
    Norwegian MoBa cohort pregnancies of women with epilepsy not using antiseizure medication, and of women without epilepsy; periconceptional folic acid use versus none
    Dose studied
    not reported

    We found no association between folic acid supplement and preterm birth in the Epilepsy without ASM group or in the No epilepsy group (Table 2).”

    Quoted verbatim from Folic Acid and Risk of Preterm Birth, Preeclampsia, and Fetal Growth Restriction Among Women With Epilepsy: A Prospective Cohort Study.cohortPermalink
  7. All-site cancer incidencecontestedMoved: no difference foundEffect, as reportedRR1.06[0.99 to 1.13]Evidence: ModeratePaper: PMID 233525522013An author is affiliated with a producer
    Who
    Adults in 13 randomised trials of folic acid versus placebo (10 trials in people with or at high risk of cardiovascular disease, 3 in patients with prior colorectal adenoma); mean age 64 years
    Dose studied
    0.5 to 5 mg folic acid daily in all trials but one (40 mg daily); one trial compared 2.5 mg with 0.02 mg

    Allocation to folic acid treatment did not have any statistically significant effect on overall cancer incidence, with 1904 (7.7%) first events in 24,799 participants allocated folic acid versus 1809 (7.3%) in 24,822 allocated control (RR 1.06; 95% CI 0.99–1.13, p=0.10: Figure 1).”

    Quoted verbatim from Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals.meta-analysisPermalink
  8. All-cause mortalityMoved: no difference foundEvidence: ModeratePaper: PMID 364324342022
    Who
    1553 postmenopausal women in the Women's Health Initiative diagnosed with invasive breast cancer, who completed a food frequency questionnaire before and after diagnosis; change in dietary folate/folic acid intake from before to after diagnosis, mean follow-up 16.1 years
    Dose studied
    not reported

    Furthermore, changes in dietary folate/folic acid or vitamin B12 intake were not associated with all-cause or breast cancer mortality after adjustment of other prognostic and dietary factors (Table 2 and Table 3).”

    Quoted verbatim from Changes in Dietary Intake of Methionine, Folate/Folic Acid and Vitamin B12 and Survival in Postmenopausal Women with Breast Cancer: A Prospective Cohort Study.cohortPermalink
  9. Lung cancer incidenceMoved: no difference foundEffect, as reportedHR1.09[0.91 to 1.3]Evidence: ModeratePaper: PMID 308384352020
    Who
    Black and white adults aged 40-79 in the Southern Community Cohort Study, southeastern US; dietary intake of synthetic folic acid from foods (fortification), highest vs lowest quartile, fully-adjusted model
    Dose studied
    dietary food folic acid intake per 1,000 kcal, highest vs lowest quartile (FFQ)

    When we further investigated natural dietary folate (“food folate”) and synthetic folic acid (“food folic acid”) intakes from foods separately (Table 4), neither of them were associated with lung cancer risk (food folate: HR=1.00, 95% CI=0.84–1.19, P-trend=0.79; food folic acid: HR=1.09, 95% CI=0.91–1.30, P-trend=0.44).”

    Quoted verbatim from Food intake of folate, folic acid and other B vitamins with lung cancer risk in a low-income population in the Southeastern United States.cohortPermalink
  10. Gestational age at delivery (length of gestation)Moved: no difference foundEvidence: ModeratePaper: PMID 387834132024Industry funded
    Who
    Pregnant women in South Australia randomised at 12-16 weeks gestation to a prenatal multivitamin and mineral supplement with 800 µg/day folic acid or the same formulation without folic acid, until 36 weeks; multivitamin and mineral content identical in both arms
    Dose studied
    800 µg/day folic acid versus 0 µg/day, in a prenatal multivitamin and mineral supplement

    There were no significant differences between the groups for birth gestational age, weight and length, except for head circumference, which was lower in the 0 µg FA/day supplement group compared to the 800 µg FA/day group (mean difference: −0.9 cm; 95% CI, −1.8, −0.1, p = 0.04) (Table 2).”

    Quoted verbatim from Maternal serum unmetabolized folic acid concentration following multivitamin and mineral supplementation with or without folic acid after 12 weeks gestation: A randomized controlled trial.RCTPermalink
  11. Interleukin-6 concentrationMoved: no difference foundEffect, as reportedSMD−0.04[−1.08 to 1.01]Evidence: ModeratePaper: PMID 386493472024
    Who
    Adults with type 2 diabetes mellitus; two randomized placebo-controlled trials pooled for IL-6
    Dose studied
    not reported

    Only two trials assessed the effect of folate on IL-6; the evidence from the random-effect meta-analysis showed a small effect size, and this also not significant, SMD = −0.04, 95%CI (−1.08, 1.01), p = 0.95.”

    Quoted verbatim from Folic acid supplementation on inflammation and homocysteine in type 2 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials.meta-analysisPermalink
  12. Fasting blood glucoseMoved: lowersEffect, as reportedMD−2.17[−3.69 to −0.65]Evidence: ModeratePaper: PMID 343718672021
    Who
    Adults in randomized controlled trials of folic acid supplementation (pooled, 24 studies)
    Dose studied
    not reported

    Results revealed significant reductions in FBG (weighted mean difference (WMD): -2.17 mg/dL, 95% CI: -3.69, -0.65, p = 0.005), fasting insulin (WMD: -1.63 pmol/L, 95% CI: -2.53, -0.73, p < 0.001), and HOMA-IR (WMD: -0.40, 95% CI: -0.70, -0.09, p = 0.011) following folic acid supplementation.”

    Quoted verbatim from Folic Acid Supplementation Improves Glycemic Control for Diabetes Prevention and Management: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.meta-analysisPermalink
  13. C-reactive protein concentrationMoved: lowersEffect, as reportedMD−0.59[−0.85 to −0.33]Evidence: ModeratePaper: PMID 343718372021
    Who
    Participants in 12 randomized controlled trials of folic acid supplementation versus placebo (pooled)
    Dose studied
    not reported

    The pooled analysis revealed that serum concentrations of CRP (WMD: -0.59 mg/L, 95% CI -0.85 to -0.33, p < 0.001) were significantly reduced following folic acid supplementation compared to placebo, but did not affect serum concentrations of IL-6 (WMD: -0.12, 95% CI -0.95 to 0.72 pg/mL, p = 0.780) or TNF-α (WMD: -0.18, 95% CI -0.86 to 0.49 pg/mL, p = 0.594).”

    Quoted verbatim from Effects of Folic Acid Supplementation on Inflammatory Markers: A Grade-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.meta-analysisPermalink
  14. Colorectal cancer incidenceMoved: no difference foundEffect, as reportedOR0.95[0.59 to 1.53]Evidence: Limitedreplicated ×1Paper: PMID 321404322020
    Who
    Women aged 40-80 living in rural East Azerbaijan, Iran; 135 colorectal cancer cases matched to 270 controls; any history of folic acid supplement intake vs none
    Dose studied
    folic acid supplement 0.4 mg/day (2.8 mg/week), prescribed to women of child-bearing age; recorded history of intake

    There was no significant association between folic acid supplementation and colorectal cancer risk (OR 0.95, 95% CI 0.59–1.53) for those with history of folic acid intake compared to no history of intake.”

    Quoted verbatim from Folic Acid Supplement Intake and Risk of Colorectal Cancer in Women; A Case Control Study.case-controlPermalink
  15. Incidence of cardiovascular disease (composite)Moved: lowersEffect, as reportedRR0.85[0.76 to 0.96]Evidence: Very limitedPaper: PMID 210882922011
    Who
    Patients with ESRD or advanced chronic kidney disease (creatinine clearance below 30 ml/min), seven randomized trials
    Dose studied
    not reported

    When pooling the seven trials, folic acid therapy reduced the risk of CVD by 15% (RR, 0.85; 95% CI, 0.76 to 0.96; P = 0.009).”

    Quoted verbatim from Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis.meta-analysisPermalink
  16. All-site cancer incidencecontestedMoved: raisesEvidence: Very limitedPaper: PMID 361566602022
    Who
    Children of mothers with epilepsy who filled antiseizure medication prescriptions (Denmark, Norway, Sweden registers); prenatal exposure to filled prescriptions of high-dose folic acid (1 mg or 5 mg tablets) versus none; subgroup of mothers with epilepsy using antiseizure medication, cancer before age 20
    Dose studied
    high-dose folic acid, at least 1 filled prescription of 1 mg or 5 mg tablets between 90 days before pregnancy and birth

    In children of mothers with epilepsy who filled prescriptions for ASM, a 3.0-fold (95% CI, 1.1-fold to 7.9-fold) increased risk of childhood cancer associated with exposure to high-dose folic acid was observed.”

    Quoted verbatim from Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy.cohortPermalink
  17. Gestational hypertension incidenceMoved: no difference foundEffect, as reportedRR1.03[0.98 to 1.09]Evidence: Very limitedPaper: PMID 262604062016
    Who
    Pregnant women in prospective studies of periconceptional folic acid alone
    Dose studied
    not reported

    Pooled results indicated that folic acid fortification alone was not associated with the occurrence of gestational hypertension [relative risk (RR) = 1.03, 95% confidence interval (CI): 0.98-1.09, P = 0.267] and pre-eclampsia (RR = 0.99, 95% CI: 0.90-1.08, P = 0.738).”

    Quoted verbatim from Periconceptional folic acid fortification for the risk of gestational hypertension and pre-eclampsia: a meta-analysis of prospective studies.meta-analysisPermalink
  18. Pre-eclampsia incidenceMoved: no difference foundEffect, as reportedRR0.99[0.9 to 1.08]Evidence: Very limitedPaper: PMID 262604062016
    Who
    Pregnant women in prospective studies of periconceptional folic acid alone
    Dose studied
    not reported

    Pooled results indicated that folic acid fortification alone was not associated with the occurrence of gestational hypertension [relative risk (RR) = 1.03, 95% confidence interval (CI): 0.98-1.09, P = 0.267] and pre-eclampsia (RR = 0.99, 95% CI: 0.90-1.08, P = 0.738).”

    Quoted verbatim from Periconceptional folic acid fortification for the risk of gestational hypertension and pre-eclampsia: a meta-analysis of prospective studies.meta-analysisPermalink
  19. Mean arterial pressureMoved: lowersEvidence: Very limitedPaper: PMID 158931702005
    Who
    Patients with ischemic heart disease, acute effect after a single oral dose
    Dose studied
    30 mg folic acid single oral dose vs placebo

    Folate was associated with a reduction in mean arterial pressure (100 +/- 12 mm Hg vs. 96 +/- 11 mm Hg, placebo vs. folate, p < 0.03).”

    Quoted verbatim from High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease.crossoverPermalink
  20. Colorectal adenoma recurrence after polypectomycontestedMoved: lowersEvidence: Very limitedPaper: PMID 186802282008
    Who
    Patients with colorectal adenomas at a VA Medical Center, polyps removed at baseline colonoscopy
    Dose studied
    5 mg folic acid daily vs matched placebo for 3 years

    High dose folic acid supplementation is associated with a significant reduction in the recurrence of colonic adenomas suggesting that folic acid may be an effective chemopreventive agent for colorectal neoplasia.”

    Quoted verbatim from Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial.RCTPermalink
  21. Colorectal adenoma recurrence after polypectomycontestedMoved: no difference foundEffect, as reportedRR0.82[0.59 to 1.13]Evidence: Very limitedPaper: PMID 198644092009
    Who
    Participants of the Health Professionals Follow-Up Study and Nurses' Health Study with prior adenoma, randomised to folic acid or placebo; whole-population primary endpoint
    Dose studied
    1 mg/d

    Incidence of at least one recurrent adenoma was not significantly associated with folic acid supplementation [relative risk (RR): 0.82; 95% CI: 0.59,1.13; P = 0.22].”

    Quoted verbatim from A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma.RCTPermalink
  22. Preterm birth incidenceMoved: no difference foundEffect, as reportedRR1.01[0.73 to 1.38]Evidence: Very limitedreplicated ×1Paper: PMID 235435472013
    Who
    Pregnant women in randomised trials of oral folic acid alone or with other micronutrients versus no folic acid · n = 2,959
    Dose studied
    not reported

    This review found that folic acid supplementation has no impact on pregnancy outcomes such as preterm birth (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.73 to 1.38; three studies, 2959 participants), and stillbirths/neonatal deaths (RR 1.33, 95% CI 0.96 to 1.85; three studies, 3110 participants).”

    Quoted verbatim from Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes.meta-analysisPermalink

No dose is advised.